Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV). We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML. Natalizumab treatment duration and prior use of immunosuppressive therapies are established risk factors for development of PML in natalizumab-treated patients. With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV. The availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Recommendations for clinical management of patients with MS and use of natalizumab are provided based on the presence of these three risk factors. The identification of risk factors that increase the likelihood of PML in natalizumab-treated patients can facilitate benefit–risk discussions between health care professionals and patients. Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development.
YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinN. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–66.
3.
PolmanCHO’ConnorPWHavrdovaEHutchinsonMKapposLMillerDH. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
4.
RudickRAStuartWHCalabresiPAConfavreuxCGalettaSLRadueEW. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
MajorEO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med2010; 61: 35–47.
7.
CalabreseLHMolloyES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis2008; 67(Suppl 3): iii64–iii65.
8.
MolloyESCalabreseLH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum2009; 60: 3761–3765.
9.
TanCSKoralnikIJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol2010; 9: 425–437.
10.
CarsonKRFocosiDMajorEOPetriniMRicheyEAWestDP. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol2009; 10: 816–824.
11.
Kleinschmidt-DeMastersBKTylerKL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med2005; 353: 369–374.
12.
Langer-GouldAAtlasSWGreenAJBollenAWPelletierD. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med2005; 353: 375–381.
13.
Van AsscheGVan RanstMSciotRDuboisBVermeireSNomanM. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med2005; 353: 362–368.
14.
YousryTAMajorEORyschkewitschCFahleGFischerSHouJ. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med2006; 354: 924–933.
15.
PadgettBLWalkerDLZuRheinGMEckroadeRJDesselBH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet1971; 1: 1257–1260.
16.
EgliAInfantiLDumoulinABuserASamaridisJSteblerC. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis2009; 199: 837–846.
17.
KeanJMRaoSWangMGarceaRL. Seroepidemiology of human polyomaviruses. PLoS Pathog2009; 5: e1000363.
18.
CarterJJMadeleineMMWipfGCGarceaRLPipkinPAMinorPD. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst2003; 95: 1522–1530.
19.
KnowlesWAPipkinPAndrewsNVyseAMinorPBrownDW. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol2003; 71: 115–123.
20.
StoltASasnauskasKKoskelaPLehtinenMDillnerJ. Seroepidemiology of the human polyomaviruses. J Gen Virol2003; 84: 1499–1504.
21.
WeberFGoldmannCKramerMKaupFJPickhardtMYoungP. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol2001; 49: 636–642.
22.
VerbeeckJVanAGRydingJWollantsERansKVermeireS. JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?Gut2008; 57: 1393–1397.
23.
MatosADuqueVBeatoSda SilvaJPMajorEMelico-SilvestreA. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol2010; 82: 494–504.
24.
ChestersPMHeritageJMcCanceDJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis1983; 147: 676–684.
25.
TanCSChenYViscidiRPKinkelRPSteinMCKoralnikIJ. Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol2010; 9: 565–566.
26.
SunyaevSRLugovskoyASimonKGorelikL. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet2009; 5: e1000368.
27.
CliffordDBDeLASimpsonDMArendtGGiovannoniGNathA. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol2010; 9: 438–446.
28.
LindaHvon HeijneAMajorEORyschkewitschCBergJOlssonT. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med2009; 361: 1081–1087.
29.
WenningWHaghikiaALaubenbergerJCliffordDBBehrensPFChanA. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med2009; 361: 1075–1080.
30.
HartungHP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol2009; 8: 28–31.
31.
SandrockAHotermansCRichmanS. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab treatment duration, and anti-JCF antibody status. Neurology2011; 76(Suppl 4): A248.
KapposLFoleyJGoldROlssonTVermerschPBozicC. Overview of survival outcome and functional status in postmarketing cases of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler J2011; 17: S131.
34.
VermerschPFoleyJGoldRKapposLOlssonTCadavidD. Overview of survival outcome and functional status in postmarketing cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab. Eur J Neurol2011; 18: 58.
35.
SubramanyamMPlavinaTLeeSNjengaMGorelikLNatarajanG. Anti-JCV antibodies are consistently detected prior to and after PML diagnosis in natalizumab-treated MS patients. Neurology2011; 76: A636–A637.
36.
SandrockAHotermansCRichmanSNatarajanALeeSPlavinaT. Risk stratification for progressive multifocal leukoencephalopathy in multiple sclerosis patients using natalizumab. J Neurol2011; 258: S23.
37.
BozicCcristianoLHydeR. Utilization and safety of natalizumab in patients with relapsing multiple sclerosis. Mult Scler2010; 16(Suppl 10): S315.
38.
GorelikLLernerMBixlerSCrossmanMSchlainBSimonK. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol2010; 68: 295–303.
39.
BloomgrenGRichmanSHotermansCSubramanyamMGoelzSNatarajanA. Contribution of natalizumab treatment duration, prior immunosuppressant use, and anti-JC virus antibody status to the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Mult Scler J2011; 17(Suppl. 10): S451.
40.
BozicCRichmanSPlavinaT. Prevalence of anti-JCV antibodies in MS patients receiving or considering treatment with natalizumab: baseline results of STRATIFY-1. Neurology2011; 76(Suppl 4): A598.
41.
ThompsonJPNoyesKDorseyERSchwidSRHollowayRG. Quantitative risk-benefit analysis of natalizumab. Neurology2008; 71: 357–364.
